{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:12:44Z","timestamp":1791443564575,"version":"4.3.3"},"reference-count":93,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Elite Ed)"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a hematologic malignancy with a poor prognosis and high relapse rates, especially in high-risk patients and older adults. Conventional treatment modalities confer limited benefit, specifically in relapsed and refractory cases. Antibody drug conjugates (ADCs) are a rapidly advancing treatment option that provides a novel approach to treating AML. The design and mechanistic aspects of ADCs have also been discussed. ADCs combine cytotoxic chemotherapeutic drugs with the specificity of monoclonal antibodies. This review primarily focuses on the current role of ADCs in the treatment of AML, including approved agents such as gemtuzumab ozogamicin, as well as others. Moreover, challenges associated with the use of ADCs have been explored, including resistance mechanisms, drug stability, immunogenicity, and cost. This review also highlights and summarizes various ongoing and completed clinical trials, which may provide insight into this treatment approach. Future advancements in AML treatment, including the use of nanoparticles or nanostructures, have also been discussed. In conclusion, this comprehensive review sheds light on the current and prospective future directions of ADCs in the treatment of AML, highlighting their potential to significantly alter the therapeutic landscape for this cancer.<\/jats:p>","DOI":"10.31083\/fbe39323","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:00:02Z","timestamp":1774947602000},"source":"Crossref","is-referenced-by-count":2,"title":["Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid Leukemia"],"prefix":"10.31083","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5909-496X","authenticated-orcid":true,"given":"Aayushi C.","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, 380009 Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6048-1849","authenticated-orcid":true,"given":"Sunayna G.","family":"Saluja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, 380009 Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0348-1225","authenticated-orcid":true,"given":"Jeel D.","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, 380009 Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3314-3807","authenticated-orcid":true,"given":"Shreeja H.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, 380009 Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4989-2913","authenticated-orcid":true,"given":"Rajanikant","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Product Development, Granules Pharmaceuticals Inc., Chantilly, VA 20151, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-0986","authenticated-orcid":true,"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, 380009 Ahmedabad, Gujarat, India"},{"name":"Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, 140401 Rajpura, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-1319","authenticated-orcid":true,"given":"Kiran","family":"Dudhat","sequence":"additional","affiliation":[{"name":"School of Pharmacy, RK University, 360020 Rajkot, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-4541","authenticated-orcid":true,"given":"Bhupendra G.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, 73000 Nakhon Pathom, Thailand"},{"name":"Now with Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, 391760 Vadodara, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"ref1","unstructured":"Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. StatPearls Publishing: Treasure Island (FL). 2023."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rose-Inman H, Kuehl D. Acute Leukemia. Hematology\/oncology Clinics of North America. 2017; 31: 1011\u20131028.","DOI":"10.1016\/j.hoc.2017.08.006"},{"key":"ref3","unstructured":"Global Cancer Observatory Internet. 2023. Available at: https:\/\/gco.iarc.fr\/ (Accessed: 6 September 2023)."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Arora RS, Arora B. Acute leukemia in children: A review of the current Indian data. South Asian Journal of Cancer. 2016; 5: 155\u2013160.","DOI":"10.4103\/2278-330X.187591"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. New England Journal of Medicine. 2006, 354: 166\u2013178. https:\/\/www.nejm.org\/doi\/full\/","DOI":"10.1056\/nejmra052603"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. The New England Journal of Medicine. 2015; 373: 1136\u20131152.","DOI":"10.1056\/NEJMra1406184"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"De Kouchkovsky I, Abdul-Hay M. \u2018Acute myeloid leukemia: a comprehensive review and 2016 update\u2019. Blood Cancer Journal. 2016; 6: e441.","DOI":"10.1038\/bcj.2016.50"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Walter RB. Brief overview of antibody-drug conjugate therapy for acute leukemia. Expert Opinion on Biological Therapy. 2021; 21: 795\u2013799.","DOI":"10.1080\/14712598.2020.1817373"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Jabbour E, Paul S, Kantarjian H. The clinical development of antibody-drug conjugates - lessons from leukaemia. Nature Reviews. Clinical Oncology. 2021; 18: 418\u2013433.","DOI":"10.1038\/s41571-021-00484-2"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Stokke JL, Bhojwani D. Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia. Journal of Clinical Medicine. 2021; 10: 3556.","DOI":"10.3390\/jcm10163556"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Medicine. 2021; 10: 4677\u20134696.","DOI":"10.1002\/cam4.4052"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-Drug Conjugates: A Comprehensive Review. Molecular Cancer Research: MCR. 2020; 18: 3\u201319.","DOI":"10.1158\/1541-7786.MCR-19-0582"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Mecklenburg L. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists. Toxicologic Pathology. 2018; 46: 746\u2013752.","DOI":"10.1177\/0192623318803059"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Marei HE, Cenciarelli C, Hasan A. Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell International. 2022; 22: 255.","DOI":"10.1186\/s12935-022-02679-8"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Hoffmann RM, Coumbe BG, Josephs DH, Mele S, Ilieva KM, Cheung A, et al. Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology. 2018; 7: e1395127.","DOI":"10.1080\/2162402X.2017.1395127"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: Promises and challenges. MAbs. 2021; 13: 1951427.","DOI":"10.1080\/19420862.2021.1951427"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharmaceutica Sinica. B. 2020; 10: 1589\u20131600.","DOI":"10.1016\/j.apsb.2020.04.012"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-Drug Conjugates: The New Frontier of Chemotherapy. International Journal of Molecular Sciences. 2020; 21: 5510.","DOI":"10.3390\/ijms21155510"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019; 125: 2474\u20132487.","DOI":"10.1002\/cncr.32116"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Gogia P, Ashraf H, Bhasin S, Xu Y. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers. 2023; 15: 3886.","DOI":"10.3390\/cancers15153886"},{"key":"ref21","unstructured":"Monoclonal Antibody Side Effects \u2014American Cancer Society. 2023. Available at: https:\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/immunotherapy\/monoclonal-antibodies.html (Accessed: 11 September 2023)."},{"key":"ref22","unstructured":"Overview of therapeutic monoclonal antibodies \u2013 UpToDate. 2023. Available at: https:\/\/www.uptodate.com\/contents\/overview-of-therapeutic-monoclonal-antibodies (Accessed: 11 September 2023)."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Pettinato MC. Introduction to Antibody-Drug Conjugates. Antibodies (Basel, Switzerland). 2021; 10: 42.","DOI":"10.3390\/antib10040042"},{"key":"ref24","unstructured":"Monoclonal Antibodies - NCI. 2023. Available at: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/monoclonal-antibodies (Accessed: 11 September 2023)."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017; 130: 2373\u20132376.","DOI":"10.1182\/blood-2017-09-797712"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Baron J, Wang ES. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Review of Clinical Pharmacology. 2018; 11: 549\u2013559.","DOI":"10.1080\/17512433.2018.1478725"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduction and Targeted Therapy. 2022; 7: 93.","DOI":"10.1038\/s41392-022-00947-7"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Yaghoubi S, Karimi MH, Lotfinia M, Gharibi T, Mahi-Birjand M, Kavi E, et al. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. Journal of Cellular Physiology. 2020; 235: 31\u201364.","DOI":"10.1002\/jcp.28967"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. Journal of the National Cancer Institute. 2019; 111: 538\u2013549.","DOI":"10.1093\/jnci\/djz035"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules (Basel, Switzerland). 2020; 25: 4764.","DOI":"10.3390\/molecules25204764"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Fu Y, Ho M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antibody Therapeutics. 2018; 1: 33\u201343.","DOI":"10.1093\/abt\/tby007"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Sheyi R, de la Torre BG, Albericio F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics. 2022; 14: 396.","DOI":"10.3390\/pharmaceutics14020396"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharmaceutica Sinica. B. 2021; 11: 3889\u20133907.","DOI":"10.1016\/j.apsb.2021.03.042"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Tang H, Liu Y, Yu Z, Sun M, Lin L, Liu W, et al. The Analysis of Key Factors Related to ADCs Structural Design. Frontiers in Pharmacology. 2019; 10: 373.","DOI":"10.3389\/fphar.2019.00373"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. MAbs. 2012; 4: 362\u2013372.","DOI":"10.4161\/mabs.19449"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody\u2013drug conjugates. Chemical Society Reviews. 2019; 48: 4361\u20134374.","DOI":"10.1039\/C8CS00676H"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2011; 17: 6417\u20136427.","DOI":"10.1158\/1078-0432.CCR-11-0486"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics. 2022; 229: 107917.","DOI":"10.1016\/j.pharmthera.2021.107917"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Mckertish CM, Kayser V. Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines. 2021; 9: 872.","DOI":"10.3390\/biomedicines9080872"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel, Switzerland). 2020; 13: 245.","DOI":"10.3390\/ph13090245"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature Reviews. Clinical Oncology. 2021; 18: 327\u2013344.","DOI":"10.1038\/s41571-021-00470-8"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Khadela A, Soni S, Shah AC, Pandya AJ, Megha K, Kothari N, et al. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon. Medical Oncology (Northwood, London, England). 2022; 40: 25.","DOI":"10.1007\/s12032-022-01884-9"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kopp A, Thurber GM. Severing Ties: Quantifying the Payload Release from Antibody Drug Conjugates. Cell Chemical Biology. 2019; 26: 1631\u20131633.","DOI":"10.1016\/j.chembiol.2019.12.001"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"McGuinness JE, Kalinsky K. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opinion on Biological Therapy. 2021; 21: 903\u2013913.","DOI":"10.1080\/14712598.2021.1840547"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacology & Therapeutics. 2018; 181: 126\u2013142.","DOI":"10.1016\/j.pharmthera.2017.07.013"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Goldenson BH, Goodman AM, Ball ED. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opinion on Biological Therapy. 2021; 21: 849\u2013862.","DOI":"10.1080\/14712598.2021.1825678"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Swaminathan M, Cortes JE. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Therapeutic Advances in Hematology. 2023; 14: 20406207231154708.","DOI":"10.1177\/20406207231154708"},{"key":"ref48","unstructured":"ADC Review, Journal of Antibody-drug Conjugates. 2023. Available at: https:\/\/www.adcreview.com\/ (Accessed: 22 October 2023)."},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules (Basel, Switzerland). 2021; 26: 5847.","DOI":"10.3390\/molecules26195847"},{"key":"ref50","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research. 2001; 7: 1490\u20131496."},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Petrich T, Korkmaz Z, Krull D, Fr\u00f6mke C, Meyer GJ, Knapp WH. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. European Journal of Nuclear Medicine and Molecular Imaging. 2010; 37: 851\u2013861.","DOI":"10.1007\/s00259-009-1356-x"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014; 32: 3021\u20133032.","DOI":"10.1200\/JCO.2014.55.3628"},{"key":"ref53","unstructured":"Levy MY, Stein AS, Vasu S, Maris MB, Advani AS, Fathi AT, et al. A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+ 3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. Inhaematologica. 2017; 102: 324\u2013324."},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018; 131: 387\u2013396.","DOI":"10.1182\/blood-2017-06-789800"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, et al. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018; 132: 1125\u20131133.","DOI":"10.1182\/blood-2018-03-841171"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, et al. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed\/refractory acute myeloid leukemia. Cancer. 2020; 126: 1264\u20131273.","DOI":"10.1002\/cncr.32657"},{"key":"ref57","unstructured":"Pivekimab Sunirine \u2014 IMGN632 \u2014 IMGN 632. ADC Review. 2023. Available at: https:\/\/www.adcreview.com\/drugmap\/pivekimab-sunirine-imgn632-imgn-632\/ (Accessed: 21 October 2023)."},{"key":"ref58","unstructured":"SGN-CD123A Drug Description. ADC Review. 2023. Available at: https:\/\/www.adcreview.com\/sgn-cd123a-drug-description\/ (Accessed: 22 October 2023)."},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, et al. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 2018; 17: 554\u2013564.","DOI":"10.1158\/1535-7163.MCT-17-0742"},{"key":"ref60","unstructured":"Zilovertamab vedotin \u2014 VLS-101 \u2014 MK-2140. ADC Review. 2023. Available at: https:\/\/www.adcreview.com\/drugmap\/zilovertamab-vedotin-vls-101-is-an-antibody-drug-conjugates-velosbio\/ (Accessed: 22 October 2023)."},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Wang M, Mei M, Barr PM, Barrientos J, de Vos S, Furman R, et al. P1231: Zilovertamab vedotin (MK-2140) for the treatment of Non-Hodgkin Lymphoma: The phase 1 dose escalation and cohort expansion WAVELINE-001 study of an anti-ROR1 antibody-drug conjugate. HemaSphere. 2022; 6: 1116\u20131117.","DOI":"10.1097\/01.HS9.0000847788.96420.63"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, et al. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. American Journal of Hematology. 2021; 96: E175\u2013E179.","DOI":"10.1002\/ajh.26136"},{"key":"ref63","unstructured":"IMGN 779 (IMGN779). ADC Review. 2023. Available at: https:\/\/www.adcreview.com\/drugmap\/imgn-779\/ (Accessed: 2 December 2023)."},{"key":"ref64","unstructured":"LOP628. ADC Review. 2023. Available at: https:\/\/www.adcreview.com\/drugmap\/lop628-lop-628\/ (Accessed: 2 December 2023)."},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, et al. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B\/T-Cell Malignancies and AML: A New Role for CD37 in AML. Molecular Cancer Therapeutics. 2015; 14: 1650\u20131660.","DOI":"10.1158\/1535-7163.MCT-15-0067"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Gupta SK, Singh P, Ali V, Verma M. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncology Reviews. 2020; 14: 448.","DOI":"10.4081\/oncol.2020.448"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Liu T, Liu X, Xiong H, Xu C, Yao J, Zhu X, et al. Mechanisms of TPGS and its derivatives inhibiting P-glycoprotein efflux pump and application for reversing multidrug resistance in hepatocellular carcinoma. Polymer Chemistry. 2018; 9: 1827\u20131839.","DOI":"10.1039\/C8PY00344K"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Shefet-Carasso L, Benhar I. Antibody-targeted drugs and drug resistance\u2013challenges and solutions. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2015; 18: 36\u201346.","DOI":"10.1016\/j.drup.2014.11.001"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Niu J, Peng D, Liu L. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. Frontiers in Oncology. 2022; 12: 896426.","DOI":"10.3389\/fonc.2022.896426"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Frontiers in Oncology. 2022; 12: 985363.","DOI":"10.3389\/fonc.2022.985363"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Molica M, Perrone S, Mazzone C, Niscola P, Cesini L, Abruzzese E, et al. CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers. 2021; 13: 3214.","DOI":"10.3390\/cancers13133214"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"San Jos\u00e9-En\u00e9riz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC Inhibitors in Acute Myeloid Leukemia. Cancers. 2019; 11: 1794.","DOI":"10.3390\/cancers11111794"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Chalouni C, Doll S. Fate of Antibody-Drug Conjugates in Cancer Cells. Journal of Experimental & Clinical Cancer Research: CR. 2018; 37: 20.","DOI":"10.1186\/s13046-017-0667-1"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. The AAPS Journal. 2015; 17: 35\u201343.","DOI":"10.1208\/s12248-014-9684-6"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Lucas AT, Moody A, Schorzman AN, Zamboni WC. Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist\u2019s Perspective. Antibodies (Basel, Switzerland). 2021; 10: 30.","DOI":"10.3390\/antib10030030"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers. 2023; 15: 713.","DOI":"10.3390\/cancers15030713"},{"key":"ref77","unstructured":"The Clinical Landscape Of ADCs In 2023 Diverse Technologies Narrow Target. 2023. Available at: https:\/\/www.clinicalleader.com\/doc\/the-clinical-landscape-of-adcs-in-diverse-technologies-narrow-target-0001 (Accessed:22 November 2023)."},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Jin Y, Edalatian Zakeri S, Bahal R, Wiemer AJ. New Technologies Bloom Together for Bettering Cancer Drug Conjugates. Pharmacological Reviews. 2022; 74: 680\u2013711.","DOI":"10.1124\/pharmrev.121.000499"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Aggarwal D, Yang J, Salam MA, Sengupta S, Al-Amin MY, Mustafa S, et al. Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy. Frontiers in Immunology. 2023; 14: 1203073.","DOI":"10.3389\/fimmu.2023.1203073"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Autio KA, Boni V, Humphrey RW, Naing A. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2020; 26: 984\u2013989.","DOI":"10.1158\/1078-0432.CCR-19-1457"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Wang Z, Li H, Gou L, Li W, Wang Y. Antibody-drug conjugates: Recent advances in payloads. Acta Pharmaceutica Sinica. B. 2023; 13: 4025\u20134059.","DOI":"10.1016\/j.apsb.2023.06.015"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Almaliti J, Miller B, Pietraszkiewicz H, Glukhov E, Naman CB, Kline T, et al. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents. European Journal of Medicinal Chemistry. 2019; 161: 416\u2013432.","DOI":"10.1016\/j.ejmech.2018.10.024"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein & Cell. 2018; 9: 33\u201346.","DOI":"10.1007\/s13238-016-0323-0"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Leung D, Wurst JM, Liu T, Martinez RM, Datta-Mannan A, Feng Y. Antibody Conjugates-Recent Advances and Future Innovations. Antibodies (Basel, Switzerland). 2020; 9: 2.","DOI":"10.3390\/antib9010002"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Houshmand M, Garello F, Circosta P, Stefania R, Aime S, Saglio G, et al. Nanocarriers as Magic Bullets in the Treatment of Leukemia. Nanomaterials (Basel, Switzerland). 2020; 10: 276.","DOI":"10.3390\/nano10020276"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Huang X, Lin H, Huang F, Xie Y, Wong KH, Chen X, et al. Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia. Dose-response: a Publication of International Hormesis Society. 2019; 17: 1559325819887048.","DOI":"10.1177\/1559325819887048"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Grav\u00e1n P, Marchal JA, Galisteo-Gonz\u00e1lez F. Improving tumor treatment: Cell membrane-coated nanoparticles for targeted therapies. Materials Today. Bio. 2025; 32: 101716.","DOI":"10.1016\/j.mtbio.2025.101716"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Lin Y, Guan X, Su J, Chen S, Fu X, Xu X, et al. Cell Membrane-Camouflaged Nanoparticles Mediated Nucleic Acids Delivery. International Journal of Nanomedicine. 2023; 18: 8001\u20138021.","DOI":"10.2147\/IJN.S433737"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Alhallak K, Sun J, Wasden K, Guenthner N, O\u2019Neal J, Muz B, et al. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia. 2021; 35: 2346\u20132357.","DOI":"10.1038\/s41375-021-01127-2"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Li J, Wang Q, Han Y, Jiang L, Lu S, Wang B, et al. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. Journal of Hematology & Oncology. 2023; 16: 65.","DOI":"10.1186\/s13045-023-01460-2"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Allegra A, Gioacchino MD, Tonacci A, Petrarca C, Gangemi S. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. Nanomaterials (Basel, Switzerland). 2021; 11: 2792.","DOI":"10.3390\/nano11112792"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Wang Y, Yang X, Liu Y, Li Y. A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia. Frontiers in Immunology. 2025; 16: 1505247.","DOI":"10.3389\/fimmu.2025.1505247"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Khadela A, Soni S, Megha K, Shah AC, Pandya AJ, Kothari N, et al. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects. Medical Oncology (Northwood, London, England). 2022; 40: 48.","DOI":"10.1007\/s12032-022-01922-6"}],"container-title":["Frontiers in Bioscience-Elite"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBE\/18\/1\/10.31083\/FBE39323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:00:24Z","timestamp":1774947624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBE\/18\/1\/10.31083\/FBE39323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1945-0494(25)00197-3"],"URL":"https:\/\/doi.org\/10.31083\/fbe39323","relation":{},"ISSN":["1945-0494","1945-0508"],"issn-type":[{"value":"1945-0494","type":"print"},{"value":"1945-0508","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"39323"}}